AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00074789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Interpersonal Therapy
Description: Psychiatric mental health nurses will meet with participants 10 times, an hour each time, over a period of 14 weeks. The nurses will continue to work with the mothers over the next 8 weeks by phone, conducting 5 fifteen minute phone sessions.
Study NCT00074789 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention control/usual care
Description: Participants will receive the usual care for depression.
Study NCT01013636 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sampling
Description: * Anaplasma diagnosis test : serology and PCR~* If presence of Anaplasma infection, proposition of treatment with doxycylin 200 mg once-a-day during 10 days
Study NCT01531244 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dactinomycin
Description: Given via ILI
Study NCT01531244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given via ILI
Study NCT01531244 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conditionally replicative adenovirus 3/5-delta
Description: Given via ILI
Study NCT03096691 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cervical pessary
Description: Silicone rings known as arabin pessary are used to support the cervix in women with a sonographic short cervix.
Study NCT02671929 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: therapeutic feedback
Description: Therapeutic feedback on the written information sent to the online therapist
Study NCT00792350 — intervention group
Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Treatment of Hepatocellular Carcinoma with Nexavar (HCC)
Study NCT00559533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5045337
Description: Administered po at escalating doses (with a starting dose of 20mg/m2/day) (5-10 cohorts)
Study NCT01380509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Capsules, single-dose, fasting
Study NCT01380509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flagyl
Description: Capsules, single-dose, fasting
Study NCT02461225 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia® FX-635™
Description: The Erchonia® FX-635™ is made up of 3 independent 17 mW, 635 nm red laser diodes that are applied for 15 minutes to each foot. The diodes are positioned around the foot such that each of the 3 laser lights is positioned between 3 and 4 inches away from, but directed toward: a) the top of the foot (dorsal aspect); b) the bottom of the foot (plantar aspect); and c) the posterior tibial nerve within the tarsal tunnel. The laser diodes laze each of these 3 areas for 15 minutes simultaneously. Each subject receives 12 total procedure administrations with the Erchonia® FX-635™ across the consecutive 6-week procedure administration phase, 2 procedure administrations per week, each procedure administration approximately evenly spaced.
Study NCT02461225 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: The Placebo Laser has the same appearance as the Erchonia® FX-635™ but does not emit any therapeutic light. It is applied for 15 minutes to each foot. The diodes are positioned around the foot such that each of the 3 laser lights is positioned between 3 and 4 inches away from, but directed toward: a) the top of the foot (dorsal aspect); b) the bottom of the foot (plantar aspect); and c) the posterior tibial nerve within the tarsal tunnel. The laser diodes laze each of these 3 areas for 15 minutes simultaneously. Each subject receives 12 total procedure administrations with the Erchonia® FX-635™ across the consecutive 6-week procedure administration phase, 2 procedure administrations per week, each procedure administration approximately evenly spaced.
Study NCT03797833 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anaesthesia
Description: Spinal anaesthesia with Bupivacain 2.5 mg and Sufentanil 5 µg
Study NCT04368286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: Pulmonary rehabilitation (respiratory rehabilitation) is a comprehensive intervention based on a comprehensive patient assessment, targeted to the treatment of patients, including but not limited to exercise training, education and behavior change, aimed at improving the physical and mental health of patients with chronic respiratory diseases and promoting long-term adherence to health-enhancing behaviors.
Study NCT03014323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: Galantamine 4 mg twice a day for 4 weeks
Study NCT04535687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib
Study NCT00067743 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lenalidomide
Description: supplied as 5 mg capsules. Dosing as directed by physician but to start at 10 mg per day
Study NCT02630186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPDL3280A
Description: A human IgG1 monoclonal antibody administered intravenously (IV)
Study NCT04393402 — intervention group
Intervention type: PROCEDURE
Intervention: lung ultrasound (LUS)
Description: Patients with Covid-19 Disease and admitted in critical care unit will be performed a LUS
Study NCT03492853 — intervention group
Intervention type: GENETIC
Intervention: DNA extraction and sequencing
Description: DNA extraction from peripheral blood and KASP sequencing
Study NCT05087407 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decomprssion and drainage seton
Description: Incision the internal sphincter over the fistula tract in intersphinteric space to achieve decompression then drainage seton will be put around external sphincter.
Study NCT02297256 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BMAC & Allograft
Description: Use of Allograft infused with adult stem cells from the bone marrow aspirate harvested from the iliac crest during posterior lumbar/lumbosacral spinal fusion.
Study NCT02297256 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Iliac Crest Bone Graft
Description: Use of iliac crest bone grafts (ICBG) during posterior lumbar/lumbosacral spinal fusion.
Study NCT02286687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02286687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02286687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO
Study NCT03014323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Galantamine
Description: Galantamine 4 mg twice a day for 4 weeks
Study NCT00600587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant erlotinib therapy
Description: 150mg erlotinib taken once daily and continued uninterrupted for 42 days before evaluation/thoracotomy/radiotherapy.
Study NCT00600587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant gemcitabine/carboplatin therapy
Description: 3 cycles of neoadjuvant gemcitabine(1250mg/m2,d1,d8)/carboplatin(AUC=5,day1) chemotherapy before evaluation/thoracotomy/radiotherapy.
Study NCT03014323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 1 capsule twice a day for 4 weeks
Study NCT01526473 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVX901
Description: Dosing will consist of AVX901 at 4 x 10E8 IU intramuscularly, given every 2 weeks for a total of three doses.
Study NCT01469078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monofer®
Description: Single Bolus Injections
Study NCT00905671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LipiScan Coronary Imaging Catheter
Description: Intravascular near infrared spectroscopic imaging of the coronary artery with a fiberoptic catheter.
Study NCT00157924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin (+) ezetimibe
Description: simvastatin (+) ezetimibe 10/20mg.
Study NCT00157924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: atorvastatin 10mg
Study NCT03014323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 capsule twice a day for 4 weeks
Study NCT01570686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 300 mg once daily
Study NCT04979351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal Massage
Description: Abdominal massage will be applied twice a day.
Study NCT02285374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir
Description: Arm 1: Switch efavirenz to dolutegravir immediately (at baseline) for 12 weeks Arm 2: Continue on pre-study regimen (unchanged) for 4 weeks and then switch efavirenz to dolutegravir for 12 weeks
Study NCT03203850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox FCT
Description: Taken orally once per day (QD) as a film coated tablet (FCT)
Study NCT03203850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phlebotomy
Description: according to investigator's decision
Study NCT03550703 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V3-Myoma
Description: Once daily oral pill of V3-Myoma
Study NCT03239587 — intervention group
Intervention type: BEHAVIORAL
Intervention: Musical Intervention
Description: Participants wait for 30 minutes in waiting area with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music.
Study NCT03239587 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draws
Description: No Musical Intervention - Control Group: Blood drawn before, and about 30 minutes after participant stands in the waiting room without music.~Musical Intervention Group: Blood drawn before, and about 30 minutes after in waiting room with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music.
Study NCT03239587 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Participants complete 2 questionnaires about anxiety and stress levels. It should take about 20-30 minutes to complete.
Study NCT00941044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist
Description: application of non-invasive NAVA in healthy volunteers
Study NCT02287064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Immune Globulin (IVIG)
Description: IVIG will be infused over a course of five days in the form of GAMMAGARD LIQUID 10% solution, available from Baxter. For neurological and autoimmune diseases 2 grams per kilogram of body weight is implemented for three months over a five day course once a month.~There is very limited reliable dose ranging data for IVIG in the treatment of any condition, and most dosing has been empiric. In our experience, we have empirically observed a more potent immunomodulatory effect from induction dose IVIG (2 g/kg) continued each month, than with the booster dose maintenance dose of 1gm/kg. Though there is no category one evidence to support this practice, neither is there such evidence to refute it. Additionally, results from previous trials of IVIG in SCAs show this dosage to be relatively safe and effective at this rate of infusion
Study NCT04287777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin gel
Description: Topical administration of Mupirocin gel 20 mg/g BID for 7 days
Study NCT04287777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin ointment
Description: Topical treatment of Mupirocin ointment 20 mg/g TID for 7 days
Study NCT04287777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical administration of Placebo (ointment) TID during 7 days
Study NCT00229255 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high frequency of meals
Description: high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
Study NCT00229255 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: twice a day meals
Description: high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
Study NCT00990496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2
Study NCT00990496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2
Study NCT00990496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV Specific Cytotoxic T Lymphocytes (CTL)
Description: CTL Infusion (3 - 5 x 10E6 cells/kg)
Study NCT03691896 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 400
Description: dose 400 UNT/day for 12 months
Study NCT03691896 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol 800
Description: dose 800 UNT/day for 12 months
Study NCT03691896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 1200
Description: dose 1200 UNT/day for 12 months
Study NCT02526940 — intervention group
Intervention type: PROCEDURE
Intervention: rectal biopsies
Description: 6 rectal biopsies
Study NCT02526940 — intervention group
Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples
Study NCT03904758 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pepsin in saliva test
Description: The presence of pepsin in the saliva will be tested in both groups of patients.
Study NCT03209427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine 100 μg
Description: Intrathecal injection of morphine100 μg
Study NCT02935023 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CIRT with systemic therapy arm
Description: carbon ion radiotherapy to the prostate(59.2GyE/16Fx to prostate and seminal vesicle) Systemic therapy:Hormonal therapy (LHRH agonist and/or antiandrogens) or chemotherapy
Study NCT00420823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Taurine 4g
Study NCT00420823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taurine 4g
Study NCT03410641 — intervention group
Intervention type: BEHAVIORAL
Intervention: Diet and antismoking advice
Description: Dietary advice with the aim of reducing participant's serum cholesterol levels, including reduction in the intake of saturated fat and cholesterol, and increased intake of polyunsaturated fat, fish, vegetables and fruit. Weight reduction was recommended for overweight men, as well as reduced consumption of sugar rich foods and drinks, and alcoholic beverages. Smokers were advised to stop smoking. The advice was given both individually and in group sessions during a five-year time period from 1972/3 until 1977/8.
Study NCT01146158 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary dissection for breast carcinomas
Description: surgery Axillary dissection
Study NCT01169233 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Bright Light Box
Description: Increased lighting used during night shifts to prevent sleepiness.
Study NCT04524507 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-titer Convalescent COVID-19 Plasma (CCP1)
Description: At least two units of CCP transfused 4-24 hours apart on Study Day 0. A third unit may be administered, if available.
Study NCT04524507 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-titer Convalescent COVID-19 plasma (CCP2)
Description: At least two units of CCP transfused 4-24 hours apart on Study Day 0. A third unit may be administered, if available.
Study NCT00852358 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: laronidase
Description: For the treatment group, intrathecal rhIDU injections will consist of 3 cc of Aldurazyme® (laronidase) (approximately 1.74 mg) diluted with 6 cc of Elliotts B® solution for a total injection of 9 cc. The diluted enzyme will be administered via a lumbar puncture (IT) on day 0 after baseline assessments. IT injections will be repeated on days 30, 60, and 90. The subsequent doses will be administered at 3-month intervals for a total of 10 doses during the two-year period. Control patients will not receive treatment, lumbar puncture, or placebo, but will undergo all other study procedures and assessments during year one. Control patients will then enter a treatment phase consisting of four IT doses at 3-month intervals.
Study NCT00852358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: laronidase
Description: For the treatment group, intrathecal rhIDU injections will consist of 3 cc of Aldurazyme® (laronidase) (approximately 1.74 mg) diluted with 6 cc of Elliotts B® solution for a total injection of 9 cc. The diluted enzyme will be administered via a lumbar puncture (IT) on day 0 after baseline assessments. IT injections will be repeated on days 30, 60, and 90. The subsequent doses will be administered at 3-month intervals for a total of 10 doses during the two-year period. Control patients will not receive treatment, lumbar puncture, or placebo, but will undergo all other study procedures and assessments during year one. Control patients will then enter a treatment phase consisting of four IT doses at 3-month intervals.
Study NCT01586013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evaluation of propofol effect using BIS
Description: propofol administered in target controlled infusion using the pharmacokinetic model of White
Study NCT03832712 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: Surgical implantation of intracranial leads for deep brain stimulation, extension cables and implantable pulse generator
Study NCT03832712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Treatment
Description: Unselective β-blockers such as Propanolol
Study NCT03769753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRE Device
Description: For use in ablating soft tissue
Study NCT02643316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Same day 4 L preparation (Polyethylene Glycol)
Description: Receive 1 gallon (4 L) of Polyethylene Glycol preparation on the morning of the colonoscopy.
Study NCT02643316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Split dose 4 L preparation (Polyethylene Glycol)
Description: Receive the split-dose regimen. Will take half (2 L) the preparation the evening before colonoscopy and half (2 L) on the morning of the procedure.
Study NCT02332616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
Study NCT02332616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Sodium Chloride
Description: Placebo
Study NCT04610827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate
Description: Guideline-recommended 3 mg/kg/day dosing
Study NCT00089505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: 200 mg taken orally
Study NCT00089505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir disoproxil fumarate
Description: 200/300 mg taken orally
Study NCT00089505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: 400/100 mg taken orally
Study NCT00089505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: 200 mg taken orally
Study NCT00089505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300 mg taken orally
Study NCT02230644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced clinical environment
Description: Surgical booths containing artwork and calming background music.
Study NCT02230644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Other distraction
Description: Such as newspaper, magazine or the news on television
Study NCT00125268 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MIRE
Description: Monochromatic near infrared photo energy (MIRE). A 30-minute application of MIRE results in a radiant exposure of 43.2 joules per square centimeter (J/cm\^2). The design of the flexible pads allows the infrared energy to be delivered perpendicular to and in contact with the involved site. MIRE applied to the skin facilitates the release of a small molecule of the free radical nitric oxide from hemoglobin and other proteins in surrounding tissue. Increased levels of nitric oxide improve the circulation of blood enhancing wound healing and reducing pain.
Study NCT00125268 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: The sham device is non-active but otherwise identical to the study device.
Study NCT04169126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 PMPBB3
Description: The study will enroll 200 patients with prodromal AD and AD dementia and 100 normal controls, men and women aged 55-80 years across core clinical criteria of prodromal AD and mild AD dementia based on IWG-2 criteria.